Dr. Simon on Durvalumab for Patients With Lung Cancer

George R. Simon, MD, FACP, FCCP
Published: Tuesday, Nov 07, 2017



George R. Simon, MD, FACP, FCCP, professor of medicine, The University of Texas MD Anderson Cancer Center, discusses durvalumab (Imfinzi) for patients with lung cancer.

Durvalumab, a PD-L1 inhibitor, recently demonstrated improved progression-free survival after patients with stage III non-small cell lung cancer (NSCLC) received definitive concurrent chemotherapy and radiation therapy in the PACIFIC trial. Durvalumab is currently in the process of getting FDA approval, says Simon.

The combination of pembrolizumab (Keytruda) with carboplatin and pemetrexed in the first-line setting for NSCLC has already been approved. The CheckMate 227 trial is currently investigating the combination of durvalumab and the CTLA-4 inhibitor ipilimumab (Yervoy) in multiple diseases, explains Simon.


George R. Simon, MD, FACP, FCCP, professor of medicine, The University of Texas MD Anderson Cancer Center, discusses durvalumab (Imfinzi) for patients with lung cancer.

Durvalumab, a PD-L1 inhibitor, recently demonstrated improved progression-free survival after patients with stage III non-small cell lung cancer (NSCLC) received definitive concurrent chemotherapy and radiation therapy in the PACIFIC trial. Durvalumab is currently in the process of getting FDA approval, says Simon.

The combination of pembrolizumab (Keytruda) with carboplatin and pemetrexed in the first-line setting for NSCLC has already been approved. The CheckMate 227 trial is currently investigating the combination of durvalumab and the CTLA-4 inhibitor ipilimumab (Yervoy) in multiple diseases, explains Simon.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Management of Adverse Events Associated with Therapies for Hematological Disorders: Nurses' PerspectiveApr 21, 20182.0
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Publication Bottom Border
Border Publication
x